OKYO — OKYO Pharma Income Statement
0.000.00%
Last trade - 00:00
HealthcareSpeculativeSmall Cap
- $98.44m
- $97.62m
2018 March 31st | C2019 March 31st | 2020 March 31st | R2021 March 31st | 2022 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 20.2 | 3.76 | 1.31 | 2.58 | 4.55 |
Operating Profit | -20.2 | -3.76 | -1.31 | -2.58 | -4.55 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.2 | -3.76 | -1.27 | -2.58 | -4.55 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.2 | -3.76 | -1.21 | -2.56 | -3.98 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.2 | -3.76 | -1.21 | -2.56 | -3.98 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.2 | -3.76 | -1.21 | -2.56 | -3.98 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -163 | -28.6 | -8.14 | -16.1 | -17.2 |
Dividends per Share |